μ- and δ-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

Brian Henry, Susan H. Fox, Alan R. Crossman, Jonathan M. Brotchie

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Long-term treatment of Parkinson's disease with levodopa is complicated by the emergence of involuntary movements, known as levodopa-induced dyskinesia. It has been hypothesized that increased opioid transmission in striatal output pathways may be responsible for the generation of dyskinesia. In this study, we have investigated the effect of blockade of opioid peptide transmission on levodopa-induced dyskinesia in a primate model of Parkinson's disease - the MPTP-lesioned marmoset. Coadministration of nonselective and μ- or δ-subtype-selective opioid receptor antagonists with levodopa resulted in a significant decrease in dyskinesia. There was no attenuation of the anti-parkinsonian actions of levodopa. These data suggest that specific μ- or δ-opioid receptor antagonists might be applicable clinically in the treatment of levodopa-induced dyskinesia in Parkinson's disease. © 2001 Academic Press.
    Original languageEnglish
    Pages (from-to)139-146
    Number of pages7
    JournalExperimental neurology
    Volume171
    Issue number1
    DOIs
    Publication statusPublished - 2001

    Keywords

    • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned marmoset
    • Dyskinesia
    • Opioid peptides
    • Opioid receptor antagonists
    • Parkinson's disease

    Fingerprint

    Dive into the research topics of 'μ- and δ-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease'. Together they form a unique fingerprint.

    Cite this